Member Info for Fruitsnveg

The last Paul Cuddon Broker Note information I have is dd 17 March 2022 and it was on the Activ-2 update but prior Sprinter results:

"Current share price: 26p

Target price: 220p"

NUMIS / Paul Cuddon – 17 March 2022

Was there a later report published after Sprinter?

DB will not have published a forecast this isn't current. Any previous forecast and rating will have been checked for accuracy against all current available information (peer,market sector - etc) before being published. I don't believe there is any previous note published by Paul Cuddon that pegged a forecast of 8p, unless I missed it? So I think this has to be new, and based on current info.

I don’t think I’ve ever come across an investor who is equally dismayed by the thought of an update or a positive broker rating. You seem happiest at the thought of the company failing. Such a strange behaviour.

DocDan, the “number” is not an arbitrary one. It is based on is level of analysis of information currently available to the the Analyst.

DB

Cheer up Costas. It could have been 3p. Or 2p. Or 1p.

It shows DN analyst believes it's worth more than you do. Which is odd, seeing as you are in investor?

Thanks Doc83. It could be that it was suspended for that time after Numis acquisition and now it's been rubber stamped as active by DB. Would be good to see if you get a response. 8p forecast, 2p higher than SP, signals some belief that they don't see the company running out of money suddenly or hitting a wall?

Doc83, Deutsch Bank bank concluded Numis takeover 7 months ago. This coverage is new, so I’d assume DB initiated.

NrN

“RnR for SNG Promotions present the first day of their Caribbean open-air fete”.

You mean this FB post? :-)

Not sure why you haven't include the scenario where they can't make any announcements due to commercial sensitivity. They will, as most will agree, be the minor partner in any such scenari,o and won't therefore be at liberty to dictate any comms output. That will be a consensus matter. That will be dictated by bigger player/s. I think this is an option as worthy of consideration as others imho.

So the hires of CFO, CMO, FC and some clinical trial peeps before Christmas was for what exactly? Fun? Please explain the logic.

Noli potestatem neglegere stultorum cunctorum.

I don't know where you get this " we won't get a deal before the P2s deliver" rehetoric? Where does it state that as a pre-requisite to a deal? Nowhere other than your head is the answer. Plenty of Biotechs strike deals before P2's. I've stated the reasons below why/ the obvious advantages to BP's in striking early. We have a pile of accumulated data (including safety), culminating with the most recent USHSA brief in Edinburgh on in vitro testing of SNG001, and everything else in between. The 100 days mission talks of "P2 Ready" candidates, not post-P2 candidates. Important distinction. I suggest you read the latest pdf of "100 Days Mission to Respond to Future Pandemic Threats" report. It'll be online if you look.

"if we Partner and give away a significant portion of the company away"

That is not true. Not all collaborations are equal.

What are the equally possible alternative scenarios here?

While Nasdaq listing is an option for a Biotech, it is not the ONLY option. Companies also have to qualify or this.

Synairgen need to consider how they will manage future cash flow requirements beyond SNG001 which surely will not remain their only 'product' once it's on it's way. A mutually beneficial collaboration with BP/BPs is an attractive option. BPs are always on the lookout for ways to replenish their pipeline, and can be willing to pay generously for investments in innovative biotech companies. They can hedge their bets by gambling on earlier stage Biotech to avoid higher price/ competition for an asset at a later stage. Equally, the technical and financial input from BP can help to speed up progress (for clinical trials in our case) and, if successful, lead to potentially generous milestone payments.

Another alternative to a collaboration could be an equity investment by a BP/BPs. This would not only allow Synairgen to retain control over its daily operations, it would also replenish the coffers. That structure suits BP because it would again allow them to hedge their bets by making multiple investments, spreading any risk. Note that GSK acquired a 10 percent stake in CureVac for £130 million and provided a cash payment of £104 million to fund R&D.

Agreed Jint. Apologies to genuine LTH’s who’ve had to endure the charade. My last response on the matter. Hopefully real news soon!

I have to say, you guys have covered yourselves in no glory today. Massive hole dig and all out of excuses. It’s sad really, how desperate you’ve become. I hope genuine investors prevail, despite your tawdry efforts.

Sakura offered her PHD research, I accepted. Waiting for her to supply the name of said paper which will be stored in electronic archive online, as they all are. No need for you to interfere in this very straight forward process docDan. None at all.

So, Sakura, the name of your research paper?

Your a numpty Sakura. You can't even express the correct charge laid against you. HInt: no one said anything about you using nebulisers or not. I can only guess that your PHD research was so awful that the University refused to Microfiche it into archives. I find that rather unsurprising as a possibility.

Just give us the name of your research paper and save yourself 130K Sakura.